Activity Dates: 11/06/2020 - 05/25/2021
This self-study activity serves as an educational tool for pharmacists seeking Board Certified Psychiatric Pharmacist (BCPP) Recertification credit and other pharmacists and health care providers seeking advanced education in patient and disease state management in the field of psychiatric pharmacy.
This recertification product consists of four clinical review articles focused on single disorders, or on one or more distinct aspects of a single psychiatric, neurologic, or substance use disorder. Authored by leading experts in the field and hosted in CPNP’s peer-reviewed journal, The Mental Health Clinician (MHC), these case-based articles will be fully referenced and offer therapeutic advice based on both evidence and longstanding clinical experience. Pearls articles focus on aspects of disease states and their pharmacotherapy that require synthesis of solutions to problems or development of practices that require judgement(s) founded on evidence, but modified or tempered by extensive clinical experience and practicalities of “real world” necessities. The articles are intended to allow you to gain greater insights into the strategies of clinical decision-making used by expert clinicians. Topics include alcohol and opioid detoxification in the ambulatory care setting, generalized anxiety disorder, mood disorders and traumatic brain injury, and seizures and new antiepileptic medications.
Psychopharmacology Pearls is an application-based continuing pharmacy education (CPE) activity. An application-based CPE activity requires that participants apply the information learned. The examination for this product often features case studies requiring that the participant apply the principles learned through the readings. Psychopharmacology Pearls includes:
You will proceed through the following steps to satisfactorily complete this course:
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Elayne D. Ansara, PharmD, BCPP, BCPS
Troy A. Moore, PharmD, MS, BCPP
Sophie Robert, PharmD, BCPP
Melody Ryan, PharmD, BCPS, BCGP, FCCP
Management of Treatment-resistant Generalized Anxiety Disorder
Cannabidiol in Epilepsy: The Indications and Beyond
Ambulatory Detoxification in Alcohol Use Disorder and Opioid Use Disorder
Traumatic Brain Injury and Mood Disorders
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Psychopharmacology Pearls product is an application-based program approved for 5 ACPE contact hours. To receive ACPE credit, pharmacists completing this programming are required to complete an evaluation of the course as well as pass an online examination.
Board Certified Psychiatric Pharmacists (BCPPs) may also receive 5 hours of BCPP Recertification Credit for the Psychopharmacology Pearls upon successful completion of an online examination.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
2020 Psychopharmacology Pearls Editorial Board
|
Reisel Berger, PharmD, BCPP Clinical Pharmacist San Francisco Department of Public Health San Francisco, CA No Relevant Financial Relationships to Disclose |
|
Benjamin Chavez, PharmD, BCPP, BCACP Associate Professor University of Colorado Skaggs School of Pharmacy Aurora, CO No Relevant Financial Relationships to Disclose |
Beth M. Hall, PharmD, BCPP |
|
Jill Kauer, PharmD, MS, BCPP Clinical Pharmacy Specialist, Psychiatry University of Iowa Hospitals and Clinics Iowa City, IA No Relevant Financial Relationships to Disclose |
|
Rex S. Lott, PharmD, BCPP BCPP Program Director Professor Emeritus of Pharmacy Practice Idaho State University - College of Pharmacy Meridian, ID No Relevant Financial Relationships to Disclose |
Amy Werremeyer, PharmD, BCPP |
All relevant relationships have been mitigated.
The articles in this learning activity were developed by the authors in conjunction with the planning committee. Each article subsequently was peer-reviewed and copyedited by the Mental Health Clinician (MHC) prior to publication. As a scholarly journal, the MHC utilizes external double-blind peer review such that reviewer details are not presented here. MHC Editorial Board policies are online.
All relevant relationships have been mitigated.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Cannabidiol My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Pregabalin, tiagabine, aripiprazole, olanzapine, risperidone, ziprasidone, quetiapine. My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Off-label use of anticonvulsants, antipsychotics, beta-blockers, alpha-agonists, stimulants, benzos, glutamate modulators in TBI-related psychiatric symptoms.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.